Before new therapies can reach patients, they must be tested in clinical trials in representative populations to show that they work and are safe. Failure to enroll enough participants in trials can delay the arrival of new ...
Mar 8, 2023
0
2
Health impacts students' ability to learn. Leaders at MUSC's Boeing Center for Children's Wellness (MUSC BCCW) believe that lessons on healthy living can be part of every student's school experience.
Feb 28, 2023
0
5
Substance use disorder (SUD) is an extremely difficult disorder to overcome, and many individuals with SUD return to regular use after repeated attempts to quit.
Feb 25, 2023
0
96
A team of researchers in the College of Medicine at the Medical University of South Carolina (MUSC) has discovered a brain circuit that inhibits motivated behaviors. They report in Nature Communications that the circuit is ...
Feb 9, 2023
0
63
A type of cell that plays a key role in pancreatic cancer can trace its origin back to a structure that forms during embryonic development, new research at MUSC Hollings Cancer Center shows. This new data, published recently ...
Jan 20, 2023
0
68
MUSC Hollings Cancer Center researchers have identified the sequence of molecular interactions that could be key to stopping the spread of cancer cells. Currently, there is no reliable therapeutic approach to prevent metastasis, ...
Jan 12, 2023
0
26
Talking, smiling, eating together—these are all social activities that are inherent to the human experience. But for some head and neck cancer survivors, they are dreaded tasks. These survivors can go through disfiguring ...
Jan 5, 2023
0
3
Sights, smells and sounds of everyday life can supply the triggers that take someone with PTSD right back to the scarring scene they're trying to forget.
Dec 28, 2022
0
124
A cross-disciplinary team of researchers in the College of Medicine at the Medical University of South Carolina (MUSC) has discovered hearing impairment in a preclinical model of autism spectrum disorder (ASD). More specifically, ...
Dec 21, 2022
0
110
MUSC Hollings Cancer Center oncologists found that using a combination monoclonal antibody (tixagevimab-cilgavimab) against the SARS-CoV-2 spike protein in patients with blood cancers prevented moderate and severe COVID cases. ...
Dec 16, 2022
0
18
